Cryoport reports Q2 EPS $2.05 vs. ($1.62) last year

Reports Q2 revenue $45.5M, consensus $41.73M. Jerrell Shelton, CEO of Cryoport (CYRX), commented, “Cryoport delivered strong, double-digit growth across all revenue streams within Life Sciences Services in the Q2, increasing 21% year-over-year and accounting for 54% of total revenue from continuing operations. Notably, revenue from BioLogistics Solutions increased 20% and BioStorage/BioServices revenue rose 28%, underscoring the growing demand for our integrated platform. Revenue from the support of commercial cell and gene therapies increased 33% year-over-year to $8.7M. This growth continues to be fueled by the increasing development and adoption of cell & gene therapies, a positive trend we believe will continue for years to come.”